Michael Paull, MD, medical director of primary/urgent care and continuous improvement at the Vancouver Clinic (TVC), explained how TVC was able to improve its hypertension metrics to align with CMS' targets.
Michael Paull, MD, medical director of primary/urgent care and continuous improvement at the Vancouver Clinic (TVC) shared how TVC was able to address its lower-than-expected hypertension metrics to better align them with CMS goals.
Transcript
What steps did TVC take to address its hypertension metrics being lower than the CMS target?
The Vancouver Clinic took many steps to address our hypertension program. We implemented a hypertension registry, developed tools within the electronic medical record to help remind clinicians when they are seeing a patient whose blood pressure is not controlled, and began doing panel coordinator outreach to our patients.
How can an organizational multispecialty initiative help improve hypertension metrics for controlling blood pressure and what can other institutions take away from TVC’s experience?
I think multispecialty clinics are in an optimal position to care for patients with high blood pressure or hypertension, given the various resources that are available and specialists to consult with, should that be necessary. There are many different approaches that organizations could take, from building a hypertension program to creating different pathways for patients to receive care, along with looking at opportunities to partner with external resources for additional support.
What are TVC’s next steps to further and refine its initiative for improving hypertension metrics?
The next step for The Vancouver Clinic is we're going to be opening a hypertension clinic that's going to be led by our pharmacy department and housed in our internal medicine residency clinic. This will open an additional pathway for patients to receive care in a timely manner.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More